Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

Author(s):

Mark D. Tyson, MD, MPH,Trinity Bivalacqua, MD, PhD

Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Prevalence and Staging of Newly Diagnosed Bladder Cancer

Now Viewing

EP: 2.Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP: 3.Recurrence and BCG Resistance in High-Risk NMIBC

EP: 4.Therapies Beyond BCG: FDA-Approved and Emerging Options

EP: 5.Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

EP: 6.CORE-001 Trial Participation and Eligibility Criteria

EP: 7.Comparing Cretostimogene and BCG Administration Methods

EP: 8.Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

EP: 9.Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

EP: 10.Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

EP: 11.Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

EP: 12.Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Video content above is prompted by the following:

Can you describe the current shortage of bacillus Calmette-Guerin, or BCG, therapy; how has this has impacted your clinical practice and management of high-risk NMIBC?